Advicenne マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Didier Laurens

最高経営責任者

€268.0k

報酬総額

CEO給与比率	75.9%
CEO在任期間	3.5yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	6.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Advicenne の収益と比較して、Didier Laurens の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€8m
Dec 31 2023	€268k	€203k	-€7m
Sep 30 2023	n/a	n/a	-€9m
Jun 30 2023	n/a	n/a	-€10m
Mar 31 2023	n/a	n/a	-€11m
Dec 31 2022	€242k	€190k	-€11m
Sep 30 2022	n/a	n/a	-€10m
Jun 30 2022	n/a	n/a	-€9m
Mar 31 2022	n/a	n/a	-€11m
Dec 31 2021	€130k	€86k	-€12m

報酬と市場: Didierの総報酬 ($USD 282.84K ) は、 German市場 ($USD 476.59K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Didierの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Didier Laurens (57 yo)

3.5yrs

在職期間

€267,987

報酬

Mr. Didier Laurens serves as Chief Executive Officer at Advicenne S.A. since May 3, 2021 and serves as its Director, MD and General Director. He is Chief Financial Officer of surgical robotics company eCen...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Didier Laurens	CEO, MD	3.5yrs	€267.99k	データなし
Laurent Cassedanne	Deputy CEO	3.2yrs	€175.30k	データなし
Isabelle Kervella	Chief Financial Officer	no data	データなし	データなし
André Ulmann	Chief Medical Officer & Non-Voting Director	3.8yrs	データなし	データなし
Hege Hellstrom	Chief Commercial Officer	no data	データなし	データなし
Robbie McCarthy	General Manager of Advicenne Inc.	no data	データなし	データなし

3.5yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: 3MMの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Didier Laurens	CEO, MD	2.4yrs	€267.99k	データなし
Laurent Cassedanne	Deputy CEO	no data	€175.30k	データなし
André Ulmann	Chief Medical Officer & Non-Voting Director	2.4yrs	データなし	データなし
Philippe Boucheron	Chairman of the Board	13.6yrs	データなし	データなし
Thibaut Roulon	Director	13.6yrs	データなし	データなし
Catherine Dunand	Director	7.7yrs	データなし	データなし
Charlotte Sibley	Independent Director	6.2yrs	€5.00k	データなし
Larry Greenbaum	Member of Scientific Advisory Board	no data	データなし	データなし
Bertrand Knebelmann	Member of Scientific Advisory Board	no data	データなし	データなし
Gema Ariceta	Member of Scientific Advisory Board	no data	データなし	データなし
Elena Levtchenko	Member of Scientific Advisory Board	no data	データなし	データなし
Detlef Bockenhauer	Member of Scientific Advisory Board	5yrs	データなし	データなし

6.2yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: 3MMの取締役会は経験豊富であると考えられます ( 6.2年の平均在任期間)。

Advicenne マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Advicenne S.A. Announces Executive Changes

Advicenne Appoints Philippe Boucheron as Chairman of Its Board of Directors

Advicenne Appoints Peter Meeus as Chief Executive Officer, Effective February 15, 2021

Recent updates

Advicenne S.A. to Report First Half, 2025 Results on Sep 18, 2025

Less than half of directors are independent

Advicenne Achieves Major Milestones in the US Due to Several Positive FDA Opinion on ADV7103

Full year 2023 earnings released: €0.67 loss per share (vs €1.16 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Advicenne S.A. to Report First Half, 2024 Results on Sep 18, 2024

Advicenne S.A. to Report Fiscal Year 2022 Results on Mar 30, 2023

Advicenne Updates on Availability of Sibnayal to Patients and Caregivers in Great Britain

Advicenne Announces Commercial Launch of Sibnayal in Great Britain

Advicenne S.A. Announces Executive Changes

Advicenne Appoints Philippe Boucheron as Chairman of Its Board of Directors

Advicenne Announces the Release of Results of a Study Showing Improved Quality of Life in Patients Living With DRTa and Treated by ADV7103

Advicenne Ordinary Shareholders' Meeting Approves Delisting from Regulated Market of Euronext Brussels

Forecast to breakeven in 2023

Advicenne Announces Positive Opinion from the French Transparency Commission (HAS) for Its Drug Sibnayal™ in dRTA

First half 2021 earnings released: €0.93 loss per share (vs €0.92 loss in 1H 2020)

Advicenne Receives Medicines and Healthcare products Regulatory Agency Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

Advicenne S.A. announced that it has received €9.42128 million in funding

Chief Executive Officer Peter Meeus has left the company

Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

Advicenne Expects Imminent Marketing Authorization for ADV7103 (Sibnayal™) for dRTA in Europe

Advicenne S.A. Provides an Update as its Operations Evolve

New 90-day high: €12.10

New 90-day high: €11.70

Advicenne Appoints Peter Meeus as Chief Executive Officer, Effective February 15, 2021

Advicenne Receives Positive CHMP Opinion Recommending Approval of ADV7103 (sibnayal) for the Treatment of Distal Renal Tubular Acidosis (dRTA)

New 90-day high: €8.46

New 90-day high: €7.58

New 90-day low: €5.96

New 90-day low: €6.46

First half earnings released

New 90-day low - €6.64

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34